TNF and rheumatoid arthritis: The ORAL Surveillance trial, which enrolled rheumatoid arthritis (RA) patients aged ≥50 with pre-existing cardiovascular risk factors, found a higher incidence of MACEs in those treated with tofacitinib (5 or 10 mg twice daily) compared with those on TNF inhibitors (HR: 1.33; 95% CI: 0.91–1.94) [32].